Objectives-To compare, in a retrospective clinicopathological study, the presentation features of patients with dementia and cortical Lewy bodies (Lewy body dementia) with those of patients with Alzheimer's disease. Methods-From a population of 426 cases from the dementia brain bank, 39 cases of Lewy body dementia and 61 cases of Alzheimer's disease with presentation details were identified. Results-The Lewy body dementia group had significantly more frequent hallucinations (23% v 3%, P = 0.006) and signs of parkinsonism (41% v 5%, P < 0-0001) than the Alzheimer's disease group. The Lewy body dimentia group also had a greater proportion of men (62% v 34%, P = 0.013).
Interest in cortical Lewy bodies found on neuropathological examination of the brains of demented patients has increased in recent years. Even though there has not been much agreement on the nosology of the condition, with different researchers using various terms ranging from Lewy body dementia to the Lewy body variant of Alzheimer's disease (for reviews, see Hansen and Galaskol and Lennox2), there have been many reports that indicate that dementia associated with cortical Lewy bodies is relatively common, with 14%-20% of demented patients having cortical Lewy bodies at necropsy. 3 6 By contrast with the presentation symptoms and signs of Alzheimer's disease, the Newcastle research group7 has reported that in their experience with cases of Lewy body dementia confirmed at necropsy "80% present with a syndrome of fluctuating cognitive impairment associated with hallucinations (usually visual), and with parkinsonian features which are often precipitated by neuroleptic drugs". These symptoms Hallucinations were recorded only if the term "hallucination" was used. When available, presentation examinations by neurologists were also analysed in a separate subcategory.
Although not specifically included in their criteria, the Newcastle group8 reported that depression occurs significantly more often in Lewy body dementia at presentation. We therefore recorded if patients were diagnosed with and treated for depression in association with the dementia presentation or in the preceding year.
Severity of disease at the time of presentation was graded according to DSM-III-R criteria'4 on review of the records. Either a "mild", "moderate", or "severe" rating was assigned, with mild indicating that the patient retained the capacity for independent living, moderate indicating that some degree of supervision was necessary, and severe indicating that continuous supervision was required. If the available clinical information for a particular case was insufficient to establish a severity rating with confidence, the less severe grade was assigned.
PATHOLOGICAL METHODS
The tissue was fixed, sectioned, and grossly inspected, and histopathological sections were then systematically taken from the neocortex of the frontal (two sections), parietal, and occipital lobes, and from the amygdala, hip-pocampus, corpus striatum, thalamus, midbrain including the substantia nigra (at least two sections at different levels), pons, medulla, and cerebellar cortex and stained with haematoxylin and eosin and Bielschowsky silver stains. The identification of cortical and subcortical Lewy bodies was based on their characteristic size, location, and staining properties, consistent with published descriptions.'5 All cases were reviewed by both neuropathologists (K-HY and JHS).
Cases in which Lewy bodies were noted in subcortical sections but not the cortex with haematoxylin and eosin were further studied by preparing a slide, using an antiubiquitin stain, of the medial temporal lobe including the hippocampus and parahippocampal gyrus. Cases in which no Lewy bodies were noted with haematoxylin and eosin were likewise further studied with antiubiquitin stain if either moderate or more severe degeneration of the substantia nigra was noted or if there were atypical clinical features.
Quantitative estimates of the density of senile plaques and neurofibrillary tangles were made from the silver stained sections. Counts of Lewy bodies were made from sections stained with either haematoxylin and eosin or antiubiquitin.
Cases showing cortical Lewy bodies were considered as a single overall group and were also subcategorised according to the presence or absence of Alzheimer's changes in the neocortex and the density of cortical Lewy bodies. The "cortical Lewy body only" subgroup comprised cases with cortical Lewy bodies and < 25 senile plaques and < 10 neurofibrillary tangles per 100 x magnification field, the "cortical Lewy body and senile plaque" subgroup comprised cases with cortical Lewy bodies and ) 25 
STATISTICAL ANALYSIS
Differences between patient groups were analysed with unpaired Student's t tests for continuous variables and Fisher's exact tests for counted variables. Two sided P values were used for all comparisons, with significance defined at the P = 0 05 level. Data for subgroups were analysed if the differences between the overall cortical Lewy body group and the Alzheimer's disease control group were significant.
Results
Of the 476 cases received during the study period, 50 were excluded due to inadequate tissue (19) , inadequate records (29), or records not documenting that the patient was demented (two). Ninety (21 %) of the the remaining 426 were found to have cortical Lewy bodies with or without other pathology. An additional four had Lewy bodies in the substantia nigra but no cortical Lewy bodies. Only one case was identified that had cortical Lewy bodies but no Lewy bodies in the substantia nigra in two sections. This case also had severe substantia nigra neuronal loss and gliosis. Twenty two of the 90 (24%) had high concentrations of cortical Lewy bodies.
Forty of the 90 cases with cortical Lewy bodies were excluded from further study due to microscopical or gross infarcts (34), unclassified degeneration (two), a meningioma (one), a subdural haematoma (one), a metastatic neoplasm (one), and alcoholic degeneration (one). One additional case was excluded due to treatment for clinical Parkinson's disease before the onset of dementia. The remaining 49 cases had cortical Lewy bodies without other dementing pathology except senile plaques or neurofibrillary tangles. Presentation details were available for 39 of these 49, comprising the overall cortical Lewy body group.
There were 83 cases identified out of the 426 that had Alzheimer's disease without other dementing pathology. Presentation details were available for 61 of these, comprising the Alzheimer's disease control group. cians or 13 of 28 as reported by neurologists), but they were reported statistically more often than for the Alzheimer's disease group (three of 59). One patient from the cortical Lewy body group was being treated for parkinsonism at the time of presentation to a physician for dementia, with the records documenting that the onset of symptoms of dementia had preceded the onset of the parkinsonism. Ten of the 39 patients with cortical Lewy bodies (26%) had two or more of the key features (fall or syncopal episode, fluctuation, hallucinations, depression, or parkinsonian signs) at presentation by contrast with none of the patients with Alzheimer's disease. Four patients with cortical Lewy bodies had three key features whereas there were none in the patients with Alzheimer's disease. Eight of the cortical Lewy body group were treated with neuroleptic medication in association with their presentations, with no cases of exaggerated or unexpected responses being noted.
The cortical Lewy body group also had a greater proportion of men 24 of 39 (62%) v 21 of 61 (34%) for the Alzheimer's disease group. All 15 cases in the Alzheimer's disease group for which key clinical features were reported were examined for cortical Lewy bodies using antiubiquitin stain; no additional cases with cortical Lewy bodies were identified.
Discussion
Albeit in a minority of cases, our results support the claims of the Newcastle group7 that many patients with Lewy body dementia present with a syndrome very different from the "typical" patient with Alzheimer's disease. Twenty six per cent of those with Lewy body dementia presented with two or more of the key features, by contrast with none of those with Alzheimer's disease. Those with Lewy body dementia had hallucinations and signs of parkinsonism reported more often than those with Alzheimer's disease, and they were noted to have a male predominance. (2) n =20 (6) n=5 (1) n =9 006 (see table 1 On the other hand, our results do not support the Newcastle group's report7 that 80% of patients with Lewy body dementia present with fluctuating cognitive impairment associated with hallucinations and parkinsonian features. Whereas 23% were reported to have had hallucinations at presentation, the other key symptoms of falls, syncope, and prominent fluctuation were reported less often and with no greater frequency than for the patients with Alzheimer's disease. Less than 50% of the patients had signs of parkinsonism documented at presentation, whether reported by neurologists or by all the physicians irrespective of specialty. Moreover, the Newcastle claim that depression occurs more often in Lewy body dementia at presentation8 was not supported by our data.
This relatively low frequency of recognition of parkinsonism at presentation also suggests that the clinical diagnostic criteria for Lewy body dementia proposed by the Nottingham9 and San Diego'0 groups would not be very sensitive for distinguishing early disease, as both require the presence of multiple parkinsonian features.
It must be emphasised that our data collection was retrospective, and the true frequency of occurrence of many of the key symptoms and signs likely was higher. We acknowledge that the absence of reports of falls, syncope, and fluctuation cannot be used to argue that they did not occur. Furthermore, our patient population may not have been representative of all cases of Lewy body dementia, as those that may have had a very rapid course and florid psychiatric features could have been neuropathologically diagnosed through other channels. Nevertheless, our data suggest that such features were not prominent in the presentations of most of the patients with Lewy body dementia.
Another explanation for the difference between our results and those of the Newcastle group8 is that our patient popula- In summary, our results corroborate the advice of the Newcastle group7 that "clinicians should be aware of the broad spectrum of clinical presentations of cortical Lewy body disease". Many patients with Lewy body dementia indeed presented with symptoms and signs different from the patient with Alzheimer's disease. In particular, the occurrence of hallucinations in association with their presentations is very noteworthy. On the other hand, many did not seem to be different from Alzheimer's disease, at least regarding the features we studied. Furthermore, the recently proposed criteria8-'0 for the clinical diagnosis of Lewy body dementia would seem not to be very sensitive in its early detection. Further work is needed to confirm our findings and to develop better clinical criteria for its early diagnosis.
